Shuttle Pharmaceuticals (NASDAQ: SHPH) — Perfil da empresa, notícias e dados financeiros
Shuttle Pharmaceuticals advances cancer treatments by developing radiation enhancers for radiotherapy to improve patient outcomes.
Shuttle Pharmaceuticals
Shuttle Pharmaceuticals (NASDAQ:SHPH) is dedicated to advancing cancer treatments through its engaging in research, development, and commercialization of innovative therapies. Their operations focus on utilizing radiation enhancers designed to improve the outcomes of radiotherapy in cancer patients, targeting both effectiveness and reduction of side effects. Shuttle Pharmaceuticals works on several projects aimed at personalizing treatment for cancer patients, including the development of novel drugs and the exploration of genetic markers to predict patient response to therapies. Their ultimate objective is to transform cancer treatment by making it more efficient, personalized, and accessible to patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Shuttle Pharmaceuticals
- Personalized radiation therapy programs, optimizing treatment efficacy by integrating genetic markers.
- Rhenium-SCT, a non-invasive skin cancer treatment targeting non-melanoma types.
- Drug repurposing platform, identifying existing drugs with potential for treating various cancers.
- Pharmacogenomics analytics services, aiding in the customization of cancer treatment plans.
- Radiation sensitizer development, enhancing the effectiveness of radiation therapy for solid tumors.
- Educational programs and support services for radiation oncologists, focusing on advanced treatment methodologies.
equipe executiva do Shuttle Pharmaceuticals
- Christopher Robert CooperInterim Co-CEO & Director
- Milton BrownCo-Founder
- Ryan TrasoliniCo-Chief Executive Officer
- Mira JungCo-Founder & Chief Scientific Officer for Biology
- Yuying LiangChief Financial Officer
- Tyvin A. RichChief Clinical Officer & Chief Medical Officer
- Michael P. Vander HoekVice President for Operations and Regulatory
Principais indicadores financeiros
Resultados divulgados pela Shuttle Pharmaceuticals, em USD.
- Cap. de mercado
- 24,8 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -16.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -11,9 mi | -11,7 mi | |
| 0 | -7,7 mi | -9,1 mi | |
| 0 | -5,9 mi | -6,6 mi | |
| 0 | -2,3 mi | -5 mi |